Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer

Jan Nyrop Jakobsen, Jens Benn Sørensen

Research output: Contribution to journalJournal articleResearchpeer-review

44 Citations (Scopus)

Abstract

Biomarker expression is increasingly being used to customize treatment in non-small cell lung cancer (NSCLC). The choice of systemic treatment usually depends on biomarker expression in the initial diagnostic biopsy taken before initiation of first-line treatment. Chemotherapy induces DNA damages in the tumor cells, and thus, biomarker expression in the tumor after systemic treatment might not be identical to biomarker expression in the diagnostic biopsy. NSCLC is highly heterogeneous and biomarker expression may vary in different areas within the same tumor. This review explores the tumor heterogeneity and chemotherapy-induced changes in EGFR biomarker status in NSCLC.
Original languageEnglish
JournalCancer Chemotherapy and Pharmacology
Volume69
Issue number2
Pages (from-to)289-99
Number of pages11
ISSN0344-5704
DOIs
Publication statusPublished - 2012

Cite this